300723 一品红
已收盘 07-09 15:00:00
资讯
新帖
简况
一品红(300723)披露召开2026年第二次临时股东大会通知,7月8日股价下跌2.36%
证券之星 · 07-08 22:16
一品红(300723)披露召开2026年第二次临时股东大会通知,7月8日股价下跌2.36%
一品红(300723)6月30日股东户数3.31万户,较上期减少8.15%
证券之星 · 07-06
一品红(300723)6月30日股东户数3.31万户,较上期减少8.15%
一品红:截止至2026年6月30日,公司股东总户数33,076户
证券之星 · 07-06
一品红:截止至2026年6月30日,公司股东总户数33,076户
一品红(300723)6月30日股东户数3.31万户,较上期减少8.15%
证券之星 · 07-02
一品红(300723)6月30日股东户数3.31万户,较上期减少8.15%
一品红:截止至2026年6月30日,公司股东总户数33,076户
证券之星 · 07-02
一品红:截止至2026年6月30日,公司股东总户数33,076户
7月1日一品红涨8.42%,新华鑫益灵活配置混合A基金重仓该股
证券之星 · 07-01
7月1日一品红涨8.42%,新华鑫益灵活配置混合A基金重仓该股
6月29日一品红涨16.83%,新华鑫益灵活配置混合A基金重仓该股
证券之星 · 06-29
6月29日一品红涨16.83%,新华鑫益灵活配置混合A基金重仓该股
一品红:痛风创新药AR882国内Ⅲ期临床试验完成全部患者入组
证券之星 · 06-29
一品红:痛风创新药AR882国内Ⅲ期临床试验完成全部患者入组
6月26日一品红跌6.79%,新华鑫益灵活配置混合A基金重仓该股
证券之星 · 06-26
6月26日一品红跌6.79%,新华鑫益灵活配置混合A基金重仓该股
一品红(300723)披露股东部分股份质押展期公告,6月23日股价上涨9.36%
证券之星 · 06-23
一品红(300723)披露股东部分股份质押展期公告,6月23日股价上涨9.36%
6月23日一品红涨9.36%,新华鑫益灵活配置混合A基金重仓该股
证券之星 · 06-23
6月23日一品红涨9.36%,新华鑫益灵活配置混合A基金重仓该股
股市必读:一品红(300723)6月22日董秘有最新回复
证券之星 · 06-23
股市必读:一品红(300723)6月22日董秘有最新回复
一品红(300723)披露全资子公司获得盐酸丙卡特罗口服溶液注册证书的公告,6月22日股价下跌0.9%
证券之星 · 06-22
一品红(300723)披露全资子公司获得盐酸丙卡特罗口服溶液注册证书的公告,6月22日股价下跌0.9%
一品红:APH03867片与AR882均为URAT1抑制剂
证券之星 · 06-22
一品红:APH03867片与AR882均为URAT1抑制剂
一品红(300723.SZ):子公司获得盐酸丙卡特罗口服溶液注册证书
智通财经 · 06-22
一品红(300723.SZ):子公司获得盐酸丙卡特罗口服溶液注册证书
每周股票复盘:一品红(300723)全资子公司创新药获临床试验受理
证券之星 · 06-21
每周股票复盘:一品红(300723)全资子公司创新药获临床试验受理
一品红(300723.SZ):子公司创新药APH03867片获得临床试验注册申请受理
智通财经 · 06-18
一品红(300723.SZ):子公司创新药APH03867片获得临床试验注册申请受理
股市必读:一品红(300723)6月17日董秘有最新回复
证券之星 · 06-18
股市必读:一品红(300723)6月17日董秘有最新回复
一品红:2025年12月中旬同意回购公司股票
证券之星 · 06-17
一品红:2025年12月中旬同意回购公司股票
一品红(300723.SZ)子公司创新药APH03571片获批开展临床试验
智通财经 · 06-10
一品红(300723.SZ)子公司创新药APH03571片获批开展临床试验
加载更多
公司概况
公司名称:
一品红药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2017-11-16
主营业务:
一品红药业集团股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是儿童药产品、慢病药产品。依托完善的创新研发体系,结合多年的市场经验,公司形成了覆盖面广、重点突出、阶梯化储备的产品结构,聚焦于特色儿童药及创新慢病药领域。截至本报告披露之日,公司(含全资及控股子公司)新增技术发明专利5项,目前,公司共有专利125项,其中国内专利114项,境外专利11项;共有商标477项,软件著作权45项。
发行价格:
17.05
{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":37.84,"timestamp":1783580595000,"preClose":37.69,"halted":0,"volume":14805164,"delay":0,"changeRate":0.004,"floatShares":419000000,"shares":451999999,"eps":0.4428,"marketStatus":"已收盘","change":0.15,"latestTime":"07-09 15:00:00","open":36.9,"high":39.16,"low":36.68,"amount":559000000,"amplitude":0.0658,"askPrice":37.85,"askSize":64,"bidPrice":37.84,"bidSize":139,"shortable":0,"etf":0,"ttmEps":0.4428,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783647000000},"marketStatusCode":5,"adr":0,"adjPreClose":37.69,"symbolType":"stock","openAndCloseTimeList":[[1783560600000,1783567800000],[1783573200000,1783580400000]],"highLimit":41.46,"lowLimit":33.92,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":451692766,"isCdr":false,"pbRate":8.79,"roa":"--","peRate":85.456188,"roe":"35.91%","epsLYR":-0.7478,"committee":0.372168,"marketValue":17092000000,"turnoverRate":0.0353,"status":0,"floatMarketCap":15862000000},"requestUrl":"/m/hq/s/300723","defaultTab":"news","newsList":[{"id":"2649699103","title":"一品红(300723)披露召开2026年第二次临时股东大会通知,7月8日股价下跌2.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649699103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649699103?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:16","pubTimestamp":1783520179,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘,一品红报收于37.69元,较前一交易日下跌2.36%,最新总市值为170.24亿元。近日,一品红药业集团股份有限公司发布《关于召开2026年第二次临时股东会的通知》。公告显示,公司将于2026年7月24日召开2026年第二次临时股东会,会议由董事会召集,现场会议时间为当日14:30,网络投票时间为同日上午9:15至下午15:00。股权登记日为2026年7月20日。登记时间为2026年7月23日,登记地点为公司证券部。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649640435","title":"一品红(300723)6月30日股东户数3.31万户,较上期减少8.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649640435","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649640435?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:37","pubTimestamp":1783330646,"startTime":"0","endTime":"0","summary":"证券之星消息,近日一品红披露,截至2026年6月30日公司股东户数为3.31万户,较5月31日减少2934.0户,减幅为8.15%。在化学制药行业个股中,一品红股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.56万户。从股价来看,2026年5月31日至2026年6月30日,一品红区间跌幅为15.1%,在此期间股东户数减少2934.0户,减幅为8.15%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600024681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649420644","title":"一品红:截止至2026年6月30日,公司股东总户数33,076户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649420644","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649420644?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:00","pubTimestamp":1783324838,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)07月06日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,股东人数一品红回复:尊敬的投资者您好,感谢您对公司的关注。截止至2026年6月30日,公司股东总户数33,076户。祝您投资愉快本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600019451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648265505","title":"一品红(300723)6月30日股东户数3.31万户,较上期减少8.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648265505","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648265505?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:38","pubTimestamp":1782985084,"startTime":"0","endTime":"0","summary":"证券之星消息,近日一品红披露,截至2026年6月30日公司股东户数为3.31万户,较5月31日减少2934.0户,减幅为8.15%。在化学制药行业个股中,一品红股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.53万户。从股价来看,2026年5月31日至2026年6月30日,一品红区间跌幅为15.1%,在此期间股东户数减少2934.0户,减幅为8.15%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200029586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648527770","title":"一品红:截止至2026年6月30日,公司股东总户数33,076户","url":"https://stock-news.laohu8.com/highlight/detail?id=2648527770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648527770?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:36","pubTimestamp":1782952570,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,股东人数一品红回复:尊敬的投资者您好,感谢您对公司的关注。截止至2026年6月30日,公司股东总户数33,076户。祝您投资愉快。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200005992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516117","title":"7月1日一品红涨8.42%,新华鑫益灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648516117?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:53","pubTimestamp":1782896027,"startTime":"0","endTime":"0","summary":"证券之星消息,7月1日一品红涨8.42%,收盘报40.42元,换手率6.62%,成交量27.74万手,成交额10.73亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为新华基金的新华鑫益灵活配置混合A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647221373","title":"6月29日一品红涨16.83%,新华鑫益灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647221373","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647221373?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:52","pubTimestamp":1782723144,"startTime":"0","endTime":"0","summary":"证券之星消息,6月29日一品红涨16.83%,收盘报37.98元,换手率6.36%,成交量26.66万手,成交额9.59亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为新华基金的新华鑫益灵活配置混合A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647321687","title":"一品红:痛风创新药AR882国内Ⅲ期临床试验完成全部患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2647321687","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647321687?lang=zh_cn&edition=full","pubTime":"2026-06-29 15:48","pubTimestamp":1782719291,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)06月29日在投资者关系平台上答复投资者关心的问题。投资者提问:疼风药国内第三期试验,之前不是说六月份结束吗,目前为何还没有通过出来?一品红回复:尊敬的投资者您好,感谢您对公司的关注。2025年11月,公司在研的痛风创新药AR882(氘泊替诺雷)国内Ⅲ期临床试验完成全部患者入组。目前,正在进行关键性Ⅲ期临床试验,试验进展顺利。此外,药品研发具有周期长、投入高、风险大等特点,敬请广大投资者谨慎决策,注意投资风险。祝您投资愉快。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900019343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","300723","06978","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646358417","title":"6月26日一品红跌6.79%,新华鑫益灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646358417","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646358417?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:59","pubTimestamp":1782464354,"startTime":"0","endTime":"0","summary":"证券之星消息,6月26日一品红跌6.79%,收盘报32.51元,换手率2.44%,成交量10.21万手,成交额3.4亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为新华基金的新华鑫益灵活配置混合A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600030816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645336832","title":"一品红(300723)披露股东部分股份质押展期公告,6月23日股价上涨9.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645336832","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645336832?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:09","pubTimestamp":1782223779,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘,一品红报收于36.22元,较前一交易日上涨9.36%,最新总市值为163.6亿元。该股当日开盘32.91元,最高36.76元,最低32.91元,成交额达7.41亿元,换手率为4.97%。近日,一品红药业集团股份有限公司发布《关于公司股东部分股份质押展期的公告》。本次质押展期后,李捍东先生累计质押股份4,090,000股,占其所持股份的29.99%,占公司总股本的1.82%。李捍东先生资信状况良好,具备相应偿还能力,质押股份无平仓风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645588142","title":"6月23日一品红涨9.36%,新华鑫益灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645588142","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645588142?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:40","pubTimestamp":1782204034,"startTime":"0","endTime":"0","summary":"证券之星消息,6月23日一品红涨9.36%,收盘报36.22元,换手率4.97%,成交量20.82万手,成交额7.41亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为新华基金的新华鑫益灵活配置混合A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645774079","title":"股市必读:一品红(300723)6月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645774079","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645774079?lang=zh_cn&edition=full","pubTime":"2026-06-23 01:08","pubTimestamp":1782148096,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘,一品红报收于33.12元,下跌0.9%,换手率2.86%,成交量11.97万手,成交额3.85亿元。公司公告汇总:全资子公司获盐酸丙卡特罗口服溶液《药品注册证书》,注册分类为化学药品3类,视同通过一致性评价,适应症覆盖多种呼吸道阻塞性疾病,批准文号有效期至2031年6月16日。药品批准文号有效期至2031年6月16日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300000622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645078733","title":"一品红(300723)披露全资子公司获得盐酸丙卡特罗口服溶液注册证书的公告,6月22日股价下跌0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645078733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645078733?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:17","pubTimestamp":1782137854,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘,一品红报收于33.12元,较前一交易日下跌0.9%,最新总市值为149.6亿元。该股当日开盘33.0元,最高33.19元,最低31.37元,成交额达3.85亿元,换手率为2.86%。一品红药业集团股份有限公司近日披露公告,其全资子公司广州一品红制药有限公司收到国家药品监督管理局签发的盐酸丙卡特罗口服溶液《药品注册证书》。药品为处方药,适用于成人及儿童,属国家医保乙类产品。药品批准文号有效期至2031年6月16日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200038851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645502858","title":"一品红:APH03867片与AR882均为URAT1抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2645502858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645502858?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:57","pubTimestamp":1782118633,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红06月22日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司不是有疼风药准备上市了吗,为何还要研发APH03867.两款有什么区别一品红回复:公司申报临床的痛风创新药APH03867片与公司在研的创新药AR882都是口服、非肽类小分子URAT1抑制剂,通过抑制URAT1活性,阻断尿酸在肾小管的重吸收,增加尿酸排泄,从而有效降低血尿酸。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200024132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645042092","title":"一品红(300723.SZ):子公司获得盐酸丙卡特罗口服溶液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2645042092","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645042092?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:08","pubTimestamp":1782115688,"startTime":"0","endTime":"0","summary":"智通财经APP讯,一品红(300723.SZ)公告,公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于盐酸丙卡特罗口服溶液的《药品注册证书》。该药品用于缓解下述疾病的呼吸道阻塞性障碍引起的呼吸困难等症状:支气管哮喘、慢性支气管炎、急性支气管炎、喘息性支气管炎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300723","BK4202","BK0239","CRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645095063","title":"每周股票复盘:一品红(300723)全资子公司创新药获临床试验受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645095063","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645095063?lang=zh_cn&edition=full","pubTime":"2026-06-21 02:30","pubTimestamp":1781980229,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总:全资子公司创新药APH03867片获临床试验注册申请受理公司公告汇总关于全资子公司创新药APH03867片获得临床试验注册申请受理的公告一品红药业集团股份有限公司全资子公司广州一品红制药有限公司自主研发的创新药APH03867片的药物临床试验申请已获国家药品监督管理局受理,适应症为痛风伴高尿酸血症。APH03867片为化学药品1类创新药,通过抑制URAT1活性,促进尿酸排泄,降低血尿酸水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","06978","BK1574","300723","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644523771","title":"一品红(300723.SZ):子公司创新药APH03867片获得临床试验注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2644523771","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644523771?lang=zh_cn&edition=full","pubTime":"2026-06-18 12:01","pubTimestamp":1781755286,"startTime":"0","endTime":"0","summary":"智通财经APP讯,一品红(300723.SZ)公告,近日,公司全资子公司广州一品红制药有限公司自主研发的创新药物APH03867片的药物临床试验申请获得国家药品监督管理局受理,并收到《受理通知书》。据悉,APH03867片是公司自主研发的一种新型口服、非肽类小分子URAT1(全称:Urate Transporter 1,中文译为:尿酸转运蛋白1)抑制剂,通过抑制肾脏中URAT1的活性,阻断尿酸在肾小管的重吸收,增加尿酸排泄,达到有效降低血尿酸的效果,可用于改善高尿酸血症和痛风症状。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1161","BK1574","06978","300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644872375","title":"股市必读:一品红(300723)6月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644872375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644872375?lang=zh_cn&edition=full","pubTime":"2026-06-18 02:05","pubTimestamp":1781719513,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘,一品红报收于32.78元,下跌1.27%,换手率1.76%,成交量7.4万手,成交额2.42亿元。董秘最新回复投资者: 董秘好,公司股价近半年跌近30%,中小投资者损失惨重。交易信息汇总资金流向6月17日主力资金净流出1463.67万元,占总成交额0.0%;游资资金净流出1155.68万元,占总成交额0.0%;散户资金净流入2619.35万元,占总成交额0.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800001602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644746792","title":"一品红:2025年12月中旬同意回购公司股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2644746792","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644746792?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:51","pubTimestamp":1781700707,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红06月16日在投资者关系平台上答复投资者关心的问题。2025年12月中旬,公司董事会同意公司以集中竞价方式回购公司部分已发行的人民币普通股(A股)股票用于维护公司价值及股东权益。回购的资金总额为不低于人民币10,000万元且不超过人民币20,000万元。回购价格不超过人民币70.00元/股(含)。截至回购期末,公司累计回购316.22 万股,占公司总股本的 0.70%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700039413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642446677","title":"一品红(300723.SZ)子公司创新药APH03571片获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2642446677","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642446677?lang=zh_cn&edition=full","pubTime":"2026-06-10 15:53","pubTimestamp":1781078020,"startTime":"0","endTime":"0","summary":"智通财经APP讯,一品红(300723.SZ)发布公告,近日,公司全资子公司广州一品红制药有限公司自主研发的创新药物APH03571片的药物临床试验申请已获得国家药品监督管理局批准,并收到《药物临床试验批准通知书》,将于近期开展临床试验。APH03571是公司研制的拟用于携带FLT3(全称:FMS-like tyrosine kinase 3)突变的复发性或难治性急性髓系白血病成人患者的治疗药品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","300723","BK0239","159992","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783598721060,"stockEarnings":[{"period":"1week","weight":-0.0675},{"period":"1month","weight":0.0859},{"period":"3month","weight":0.0513},{"period":"6month","weight":0.0088},{"period":"1year","weight":-0.2526},{"period":"ytd","weight":0.1234}],"compareEarnings":[{"period":"1week","weight":-0.0344},{"period":"1month","weight":0.0029},{"period":"3month","weight":0.0012},{"period":"6month","weight":-0.0363},{"period":"1year","weight":0.1354},{"period":"ytd","weight":0.0005}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"一品红药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"33076人(较上一季度减少8.15%)","perCapita":"12673股","listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","registeredCapital":"45169万元","survey":" 一品红药业集团股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是儿童药产品、慢病药产品。依托完善的创新研发体系,结合多年的市场经验,公司形成了覆盖面广、重点突出、阶梯化储备的产品结构,聚焦于特色儿童药及创新慢病药领域。截至本报告披露之日,公司(含全资及控股子公司)新增技术发明专利5项,目前,公司共有专利125项,其中国内专利114项,境外专利11项;共有商标477项,软件著作权45项。","listedPrice":17.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}